Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral PUVA for chronic oral graft-versus-host disease
ACTRN12613000330741Phase 2Recruiting
- Sponsor
- St Vincent's Hospital
- Start
- Feb 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methoxsalen and bergapten in chronic graft-versus-host disease (cGVHD), sponsored by St Vincent's Hospital. Primary endpoints: Oral GVHD severity and Oral mucositis severity. Started Feb 2010; status: recruiting.
02
Drugs
methoxsalenbergapten
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on ACTRN12613000330741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000330741.